FDA Label Now Backs Early Winrevair Use in PAH

FDA approved a label update for WINREVAIR (sotatercept-csrk) on 22 September 2026, adding Phase 3 HYPERION trial data specific to adults diagnosed with pulmonary arterial hypertension within the previous year. The trial cut a composite clinical-worsening endpoint from 36.9% on placebo to 10.6% on sotatercept, added to background therapy — a 76% relative risk reduction that Merck and PAH specialists are already framing as evidence for treating earlier rather than waiting for a patient to fail first-line combinations. WINREVAIR's approved indication does not change. What changes is the case a cardiologist or pulmonologist now has for referring a newly diagnosed patient sooner — against a drug that still requires hemoglobin monitoring before each early dose and costs roughly $240,000 a year at its standard schedule.

A trial built around timing, not a new population

WINREVAIR reached the market in March 2024 on the strength of STELLAR, a trial in patients with established PAH already on background therapy, and later added ZENITH data covering higher-risk, hospitalized patients. HYPERION asks a different question: does adding sotatercept soon after diagnosis, rather than after a patient has had time to progress, change the trajectory of the disease? The trial enrolled 320 adults diagnosed with PAH within the prior 12 months — more than 70% already on double background therapy, with a smaller share on triple therapy or infused prostacyclin — and randomized them 1:1 to sotatercept or placebo. The composite clinical-worsening endpoint bundled death, an unplanned PAH-related hospitalization beyond 24 hours, atrial septostomy, lung transplantation, and disease deterioration. It occurred in 10.6% of the sotatercept arm against 36.9% on placebo, a hazard ratio of 0.24 (95% CI 0.14–0.41) — a result large enough, and a trial population narrow enough, that it reads less like confirmation of an existing indication and more like a specific argument for not waiting.

Where it sits against the standard escalation path

Current PAH guidance favors risk-stratified treatment: initial combination therapy, typically an endothelin receptor antagonist (ERA) plus a PDE5 inhibitor for low- or intermediate-risk patients, with escalation to triple therapy or parenteral prostacyclins reserved for those who remain at higher risk on reassessment. HYPERION does not replace that framework — more than 70% of its participants were already on double background therapy when sotatercept or placebo was added — but it gives specialists trial-level support for adding a fourth mechanism earlier in a newly diagnosed patient's course, rather than waiting to see whether the initial combination holds. For a referring internist or cardiologist who is not the one prescribing sotatercept, the practical implication is timing: a patient recently diagnosed with PAH and already showing intermediate- or high-risk features is now a more defensible early referral to a pulmonary hypertension center, not a wait-and-see case.

Standard escalation vs. what HYPERION supports

	Standard risk-stratified escalation	Early addition, per HYPERION
When sotatercept is added	After reassessment shows persistent intermediate/high risk on double therapy	Within the first year after diagnosis, alongside background therapy
Evidence base	STELLAR (established PAH) and ZENITH (high-risk, hospitalized)	HYPERION: 320 patients diagnosed within 12 months
Clinical worsening at trial endpoint	Not the population HYPERION measured	10.6% vs. 36.9% on placebo (HR 0.24)
Monitoring burden	Same regardless of timing	Hemoglobin before each of the first 5 doses, then periodically

The approved indication is unchanged: WINREVAIR remains indicated for adults with PAH generally. HYPERION adds evidence for one timing strategy within that indication.

What it costs before a payer says yes

None of this changes WINREVAIR's price. Merck lists the drug at roughly $14,000 per vial before rebates; at the every-three-week schedule roughly two-thirds of patients require, that runs to approximately $240,000 a year. More than two years after its original approval, WINREVAIR is still billed under unclassified or miscellaneous codes — C9399, J3490, or J3590, depending on the setting — rather than a dedicated, permanent HCPCS code, which means claims still rely on NDC-level reporting rather than a single billing code payers can process automatically. Commercial and Medicare Advantage plans generally require prior authorization tied to a confirmed WHO Group 1 PAH diagnosis and, often, evidence of background therapy — criteria this label update does not itself reopen, since they are built around the diagnosis rather than its recency. What the update does give a prescriber is documentation: HYPERION is now on the label as evidence for starting sotatercept within a patient's first year of diagnosis, which is the kind of citation a prior-authorization reviewer asks for when a request arrives sooner than a payer's existing criteria anticipated.

WINREVAIR's file, by trial

1. 26 March 2024

   Original approval

   First FDA-approved activin signaling inhibitor for PAH, based on the Phase 3 STELLAR trial in patients with established disease on background therapy.

2. Later supplement

   ZENITH data added

   A separate label update incorporated Phase 3 ZENITH results in higher-risk, hospitalized PAH patients.

3. 22 September 2026

   HYPERION data added

   Label update adds evidence for adding sotatercept within the first year after a PAH diagnosis, alongside background therapy.

4. Ahead

   Guideline and payer catch-up

   PAH treatment guidelines and payer prior-authorization criteria typically take months to reflect a label update of this kind; expect gradual movement rather than an immediate practice shift.

• Reassess referral timing: a newly diagnosed PAH patient with intermediate- or high-risk features on initial workup is now a stronger case for early referral to a pulmonary hypertension center, rather than deferred until they progress on double therapy.
• Plan for the monitoring schedule: hemoglobin before each of the first five doses, then periodically, with dose adjustments possible for rising hemoglobin or falling platelets — build this into the referral conversation, not just the prescribing one.
• Expect the prior-authorization conversation to lag the label: payer criteria are built around the PAH diagnosis itself, so an early request may still need extra documentation until payer policies explicitly catch up to HYPERION.
• Don't expect the cost conversation to change: roughly $240,000 a year at standard dosing, still billed under unclassified codes — patient assistance and payer navigation remain part of starting this drug at any point in a patient's course.

Frequently asked questions

What changed for physicians on 22 September 2026?

FDA approved a label update adding Phase 3 HYPERION trial data to WINREVAIR (sotatercept-csrk, Merck) for adults diagnosed with pulmonary arterial hypertension (PAH, WHO Group 1) within the prior 12 months. WINREVAIR's approved indication — adults with PAH, added to background therapy — does not narrow or expand; what changes is the evidence base a prescriber can point to for using it soon after diagnosis rather than only in established disease.

How large was the treatment effect in HYPERION?

HYPERION randomized 320 adults with recently diagnosed PAH, most already on double or triple background therapy, to sotatercept or placebo. A composite clinical-worsening endpoint — death, PAH hospitalization, atrial septostomy, transplant, or disease deterioration — occurred in 10.6% of the sotatercept group versus 36.9% on placebo (hazard ratio 0.24, 95% CI 0.14–0.41), a 76% relative risk reduction, published in the New England Journal of Medicine.

What does starting Winrevair actually require?

Weight-based subcutaneous injection — 0.3 mg/kg starting dose, titrated to a 0.7 mg/kg target — every three weeks, at an injection site on the abdomen, thigh, or upper arm. The label requires hemoglobin monitoring before each of the first five doses (and periodically after), because the drug can raise hemoglobin enough to increase thromboembolic or hyperviscosity risk; dose adjustments follow hemoglobin and platelet trends.

Is this label update likely to change what payers cover?

Not directly. WINREVAIR's coverage criteria are built around the WHO Group 1 PAH diagnosis itself, not how recently it was made, so the label update does not, on its own, reopen a coverage question. What it gives prescribers is documentation to support an earlier-than-usual start when a payer's prior-authorization reviewer asks for evidence. The drug's list price — about $14,000 per vial, roughly $240,000 a year for patients on the every-three-week schedule — and its continued billing under unclassified biologic codes rather than a dedicated HCPCS code are unchanged by this update.